Medtronic has appointed Martin Rothman as the new vice president of medical affairs for the company’s coronary and peripheral vascular business, based in Santa Rosa, US.

Prof Rothman will join Medtronic on January 4, 2010. He has over 37 years of clinical practice in the UK as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust), where he served as director of cardiac research and development.

Prof Rothman has conducted scores of clinical trials related to interventional cardiology. He has participated as an investigator in studies of Medtronic’s Endeavor drug-eluting coronary stents. In addition, Prof Rothman has led cardiac stem cell research for heart failure treatment. He also established the largest heart attack center in Europe.

Reportedly, during his tenure at the London Chest Hospital, Prof Rothman has developed a nationally and internationally recognised training program for interventional cardiology, a medical specialty that treats patients with heart disease through minimally invasive techniques such as angioplasty and transcatheter valves.

Prof Rothman has contributed to advancing the specialty’s medical education, including the development of live case demonstrations, which enable clinicians to learn through observation and interaction with the physicians performing the procedures. Prof Rothman has also contributed to the development of medical technology for interventional cardiology.

Sean Salmon, vice president and general manager of coronary and peripheral division for cardiovascular business at Medtronic, said: “We look forward to his leadership of our office of medical affairs, which will benefit from the scientific rigor and keen insights that he has demonstrated throughout his medical career.”